APA

Fox E., Maris J. M., Widemann B. C., Goodspeed W., Goodwin A., Kromplewski M., Fouts M. E., Medina D., Cohn S. L., Krivoshik A., Hagey A. E., Adamson P. C. & Balis F. M. (20080603). A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Fox Elizabeth, Maris John M, Widemann Brigitte C, Goodspeed Wendy, Goodwin Anne, Kromplewski Marie, Fouts Molly E, Medina Diane, Cohn Susan L, Krivoshik Andrew, Hagey Anne E, Adamson Peter C and Balis Frank M. 20080603. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Fox E., Maris J. M., Widemann B. C., Goodspeed W., Goodwin A., Kromplewski M., Fouts M. E., Medina D., Cohn S. L., Krivoshik A., Hagey A. E., Adamson P. C. and Balis F. M. (20080603). A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Fox Elizabeth, Maris John M, Widemann Brigitte C, Goodspeed Wendy, Goodwin Anne, Kromplewski Marie, Fouts Molly E, Medina Diane, Cohn Susan L, Krivoshik Andrew, Hagey Anne E, Adamson Peter C and Balis Frank M. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20080603.